IBSA
1.7.2024 19:11:33 CEST | Business Wire | Press release
For the Class40 IBSA it’s time to return to Europe: sailing the boat during the wonderful Transat Québec Saint-Malo is skipper Alberto Bona, together with Pablo Santurde del Arco and Luca Rosetti, in a regatta that turns out to be a real conundrum, due to the expected weather conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240701084720/en/
Started after the storm, at 2:15 pm local time (8:15 pm Italian time), as expected the 10th edition of the Transat Québec Saint-Malo immediately proved to be very complicated. The St. Lawrence River, in fact, features currents, very unstable winds that change with the passage of a single cloud, and many variables to dominate.
A few minutes before the start, there was in fact a violent and rapid increase in the average wind speed (squall) with rain and hail, followed by a gusty and sustained wind up to 15 knots, which allowed the crafts to set off running with the wind, offering a great show as part of a very tactical first leg of the race.
Immediately after the start, Bona and the Class40 IBSA chose to keep to the right side of the race course, starting around mid-fleet and choosing to be very sparing with their manoeuvers, thus obtaining a good advantage. Indeed, those who gybed several times lost contact with the leaders of the fleet, accumulating a bit of delay.
The crew of the Class40 IBSA continued to keep to the right side of the river throughout the first hour of navigation, always remaining in the top ten positions, and even leading the fleet for a stretch off Luzon. One hour and 45 minutes after the start, Alberto and the Class40 IBSA were in third position in a race which will however see, during the river navigation, continuous changes at the top, variable wind with strong gusts and moments of very little wind. Great resilience will therefore be necessary.
“We saw a great start”, commented Antonio Melli, Vice President of IBSA Group. “This very important regatta started well and will lead us to Saint-Malo, where it all began, three seasons ago, between IBSA and Alberto Bona. Sailing has given us great satisfaction, involving many colleagues in Europe and the United States in a story of sport and values”.
With increasingly unstable weather conditions, but with expected winds up to 20 knots, the passage along the St. Lawrence is still strategic. According to Bona, the first 140 miles will be the most complicated, due to conditions and variables, and with well-defined shifts for the team: Alberto will continue to take care of navigation, keeping an eye on the instruments to define the correct tactical choices based on the orography of the river and the wind, while Pablo and Luca will have the task to sail the boat and manage the manoeuvers, keeping an eye on potential whale encounters.
For the first three days of navigation, the great river will be the protagonist; then the fleet of 25 Class40s will tackle the mouth and Newfoundland, before finding themselves in the Atlantic Ocean, where they will look for the best way to “land” in the English Channel, to then reach the finish line in Saint-Malo.
Navigation is expected to last approximately 11-12 days.
THE PROJECT: The three-year project Sailing into the Future. Together was launched in January 2022. The partnership between IBSA and skipper Alberto Bona was born on common bases and values, and aims to use sailing as a corporate communication vehicle towards the market and the nautical world. Ingenuity, courage, innovation, responsibility are elements that unites IBSA and Alberto, and the oceanic challenge, in addition to the sporting competition, also metaphorically represents the company’s history, philosophy and vision, which are always oriented towards and are part of a path that brings IBSA increasingly closer to the topic of environmental and social sustainability, with a particular focus on inclusive sailing projects for people with disabilities. In November 2022, the Route du Rhum was the first sporting stage of the project Sailing into the Future. Together. In 2023, Bona and the Class40 IBSA participated in six regattas, including the Rolex Fastnet Race and the Transat Jacques Vabre. With two victories and three podiums, the record for the highest number of miles covered in 24 hours and over 15,000 miles sailed, Bona won first place overall in the Class40 International Championship. In 2024, between April and July, he will face two of the toughest transatlantic races on the international scene: the Transat CIC from Lorient (France) to New York and the Quebec Saint-Malo (from Canada to France). |
|
THE SKIPPER: Alberto Bona is from Turin, and has a degree in philosophy. As a university student, he won the Panerai trophy aboard Stormvogel, fast ULDB and historic boat with which he crossed the Atlantic Ocean for the first time, winning the ARC with a New Zealand crew. In 2012 he took part in the Minitransat, finishing 5th, one of the best Italian results ever in this category. In 2015, he switched to the prototype category Mini 6.50 with Promostudi La Spezia: he won the Italian championship and finished second in the ocean crossing Les Sables-Azores. In 2017 he discovered the Class40: on Giovanni Soldini’s former Telecom Italia, he participated in the Transat Jacques Vabre, where he was forced to withdraw when he was in sixth place. In 2019 he was aboard the Maserati Multi 70 trimaran, one of the world’s fastest boats, where he practiced on the foils before moving on to the Figaro Beneteau 3, aboard which he participated in the Solitaire; the only Italian registered, in 2020 he finished 7th among the rookies in the first year and 16th overall. In 2021 he won the Italian offshore team title and the Europeans in mixed doubles aboard the Figaro 3. In 2022 he started the new project in partnership with IBSA: after an eighth place in the Route du Rhum 2022, in 2023 Alberto won the Class40 International Championship, closing a season with three podiums and over 15,000 miles covered. |
|
THE BOAT: Designed by French naval architect Sam Manuard and built by the JPS Production shipyard, Alberto Bona’s boat is a Class40 Mach 5 model. Its main characteristics are: scow bow – rounded and with a wider and flatter shape than standard bows – designed to stay high above the water and avoid being submerged; all-round hull, particularly performing in conditions of strong tailwinds; and a large, shielded cockpit, to face extreme conditions of navigation in as comfortable and safe as possible positions. |
|
IBSA: IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 countries on 5 continents, through the Company’s 18 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 900 million CHF, and employs over 2,200 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility. |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701084720/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom